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A review of the published and unpublished literature on bacterial resistance in human and animals was performed.
Sixty-eight articles/reports from the Democratic Republic of Congo (DRC), Mozambique, Tanzania and Zambia were
reviewed. The majority of these articles were from Tanzania. There is an increasing trend in the incidence of
antibiotic resistance; of major concern is the increase in multidrug- resistant Escherichia coli, Klebsiella pneumoniae,
Staphylococcus aureus, Vibrio cholera, non-typhoid Salmonella and other pathogens responsible for nosocomial
infections. The increase in methicillin- resistant Staphylococcus aureus and extended-spectrum beta-lactamase (ESBL)
producers in the countries under review confirms the spread of these clones worldwide. Clinical microbiology
services in these countries need to be strengthened in order to allow a coordinated surveillance for antimicrobial
resistance and provide data for local treatment guidelines and for national policies to control antimicrobial
resistance. While the present study does not provide conclusive evidence to associate the increasing trend in
antibiotic resistance in humans with the use of antibiotics in animals, either as feed additives or veterinary
prescription, we strongly recommend a one-health approach of systematic surveillance across the public and
animal health sectors, as well as the adherence to the FAO (Food and Agriculture Organization)-OIE (World
Organization of animal Health) –WHO(World Health Organization) recommendations for non-human antimicrobial
usage.Introduction
The introduction of penicillin, in the early 1940s, was
perceived as marking the end of infectious diseases [1].
However, the emergence of resistant strains was
reported just a few years after its use. Since then, resist-
ant clones to various classes of antibiotics have been
found to spread worldwide [2]. In some areas, more than
90% resistance has been reported to commonly used an-
tibiotics such as penicillin, ampicillin, co-trimoxazole
and gentamicin [3]. The overuse of antibiotics in human
and animals has contributed to the emergence of resist-
ant clones [4,5]. It is a fact that the availability of antimi-
crobials and their proper use have reduced morbidity* Correspondence: mshana72@yahoo.com
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reproduction in any medium, provided the orand mortality due to infectious disease [http://www.cdc.
gov/drugresistance/index.html]. In developed countries,
the use of antibiotics is strictly controlled, which is not
the case in developing countries. The treatment of bac-
terial infections in Africa is largely empirical and in most
instances, there are no laboratory results to guide ther-
apy. Moreover, there are no data on common bacterial
isolates and their susceptibility patterns from larger sur-
veillance studies aimed at developing tools for thera-
peutic guidance. Developing countries bear 95% of the
global infectious diseases burden and rely on empirical
antimicrobial treatment to counteract these diseases [6].
This has resulted in many infectious diseases, once easily
curable, to become untreatable [7-9].
The burden of antimicrobial resistance (AMR) is rapidly
growing across antibiotic classes. The emergence of
methicillin- resistant Staphylococcus aureus (MRSA) clonesl Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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issue of public health importance [10]. Recently, the emer-
gence of NDM-1 has made infection due to multi-resistant
gram negative bacteria untreatable, especially in developing
countries where there is no alternative treatment available
[11]. Unfortunately, coordinated surveillance of the clones
involved is lacking, especially in developing countries in
Africa.
This review was undertaken to summarize the patterns
and trends of resistance to commonly used antibiotics
among common bacterial isolates from humans and ani-
mals from 1990s to 2012 in Democratic Republic of
Congo (DRC), Mozambique, Tanzania and Zambia. The
data from this review will be used to provide recommen-
dations on priority research area that could address the
development and spread of antibiotic resistance in
humans and animals.Methods
In this review, literature from four different countries is
appraised and reported. Though these countries present
differences in terms of local agriculture, economy, state
of health care services, political situation, etc., they all
have no clear policy on antibiotic use hence at risk of in-
creased antibiotic resistance. Also, these countries have
all introduced the one-health concept under the South
African Centre of Infectious Diseases (SACIDS) aiming
at providing data for evidence based management of in-







Total 59 9Study design and search strategy
A systematic literature review was conducted for original
articles on bacterial isolates, resistance patterns in
humans and animals from DRC, Mozambique, Tanzania
and Zambia, published from 1990 to the end of July
2012. The study focused on all bacterial pathogens with
the exception of Mycobacterium tuberculosis. A system-
atic search of online databases including PubMed/
Medline, Embase, Popline, Global Health, Google and
Web of Knowledge was undertaken. We used the search
terms “bacterial isolate resistance patterns”, “antibiotic
use”, “antimicrobial resistance”, “microbial resistance”,
“susceptibility”, “resistance surveillance” in “human or
animal use” combined with the name of the different
countries of interest. References of all articles were
searched to identify further articles. Articles were
reviewed and publications using original data on resist-
ance in animals and humans were included. The studies’
design, setting, demographic data and microbiological
methods were appraised. All studies involved human
were approved by ethics committee and informed con-
sent obtained. We also consulted the WHO, OIE and
FAO websites for relevant publications. New linksdisplayed beside the abstracts were followed and
retrieved.
Results
Overview of study design and microbiological
susceptibility methods
A total of 68 articles published between 1990 and 2012
describing bacterial pathogens and/or antibiotic resist-
ance in humans and animals were retrieved; all articles
were included in this review. Of 68 articles 40 (59%)
reported data on the susceptibility pattern; of these 88%
used disc diffusion method (Additional file 1: Table S1).
The CLSI guideline was used in 60% of articles, 3 arti-
cles used French Society for Microbiology and 1 article
used European Committee of Antimicrobial and Suscep-
tibility Testing (EUCAST) and 12 articles did not state
the guideline used. Thirteen (33%) articles did not report
the use of control strains. The majority of the studies
were short-term clinical studies and retrospective clinical
studies while 4 were surveillance studies (3 from
Tanzania and 1 from Mozambique). The distribution of
articles by country is seen in Table 1. No articles de-
scribing antibiotic resistance in animals were found from
DRC and Mozambique. Most of the human studies from
DRC, Mozambique, Tanzania and Zambia were carried
out in urban settings in tertiary hospitals, with only one
study from Tanzania involving primary health facilities,
while 3/11 (27%) of human studies from Mozambique
involved children from a rural hospital.
Escherichia coli and Klebsiella pneumoniae causing Urinary
tract infections (UTI) and blood stream infections
Escherichia coli and Klebsiella pneumoniae have been
identified as the most common causes of Urinary Tract
Infection (UTI) in Tanzania; contributed 47% of all UTI.
Ten studies from Tanzania reported on UTI and the ma-
jority of them (9/10) were short clinical studies involving
pregnant women and children [12-21]. No data regard-
ing these species on UTI were found from DRC,
Mozambique and Zambia. Resistance rates in different
studies are seen in Table 2; Klebsiella spp showed higher
resistance rates than Escherichia coli. Among Escherichia
coli mean resistance ranges from 14% for ciprofloxacin
to 85% for ampicillin while among Klebsiella spp mean
Table 2 Antimicrobial resistance rates of Escherichia coli and Klebsiella pneumoniae from Urine Tanzania
(ref: [12-15,19-21])
Antibiotic (N*) Resistance rates in different studies % Escherichia coli (range) Mean resistance n/N* (%)
Ampicillin (518) 92, 96, 53, 98, 100, 69, 80 (53–100) 438/518 (85)
Augmentin (501) 53, 70, 88, 85, 37 (37–88) 337/501 (67)
Gentamicin (518) 7, 38, 6, 23, 32, 44 (6–44) 130/518 (25)
Co-trimoxazole (339) 80, 65, 95,97, 50 (50–97) 262/339 (77)
Ciprofloxacin (501) 8, 30, 12, 9, 13 (8–30) 72/501 (14)
Ceftriaxone (339) 51, 29, 14, 27, 19 (14–51) 95/339 (28)
Ceftazidime (306) 50, 11, 14 (11–50) 77/306 (25)
Nitrofurantoin (289) 23, 6, 13, 31(6–31) 53/289 (18)
Resistance rates in different studies Klebsiella pneumoniae % (range)
Ampicillin (193) 56, 100, 98 (56–100) 163/193(85)
Augmentin (193) 11, 78, 86 (11–86) 112/193(58)
Gentamicin (193) 11, 28, 38 (11–38) 50/193 (26)
Co-trimoxazole (193) 56, 83, 95 (95–56) 150/193 (78)
Ciprofloxacin (193) 19, 19, 44 (19–44) 53/193 (27)
Ceftriaxone (193) 33, 66, 46 (33–66) 93/193 (48)
Ceftazidime (52) 52 27/52 (52)
Nitrofurantoin (193) 18, 21, 22 (18–22) 37/193 (20)
N*=Total number of isolates tested.
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ampicillin. There is an increased trend of these isolates
to become resistant to commonly used antibiotics.
Among Escherichia coli isolates from urine, ampicillin
resistance has been found to increase from 17% in
1995–1996 [20] to more than 93% in 2009 [12,19]. In
addition, an increasing resistance trend to gentamicin
among Escherichia coli isolated from urine specimens
has been observed; the rate of gentamicin resistance in
Tanzania was found to range from 7% at the Muhimbili
National hospital (MNH) in 2003 to more than 44% in
the same hospital in 2011 [15,20].
Escherichia coli and Klebsiella pneumoniae also have
been found to cause blood stream infections, especially in
neonates [22-26]. Escherichia coli was the most common
isolate in blood stream community- acquired infections
while Klebsiella spp was the commonest isolate in health
care associated infection [22-24]. Mean resistance rates of
Escherichia coli from the blood were 2%, 15%, 28%, 37%,
38%, 55%, 57%, 76% and 95% for meropenem, ciprofloxa-
cin, ceftazidime, gentamicin, ceftriaxone, augmentin,
tetracycline, co-trimoxazole and ampicillin respectively
(Table 3). With exception for meropenem, and ciprofloxa-
cin Klebsiella spp had higher resistance rates than
Escherichia coli. Escherichia coli and Klebsiella pneumoniae
strains from the blood displayed higher rates of resistance
than those from urine specimens against common antibi-
otics such as ampicillin, co-trimoxazole and gentamicin
[22,24,25]. In this review resistance to third generationcephalosporins was observed in more than 20% of hospital-
acquired Klebsiella spp and Escherichia coli.
One study in Tanzania reported data from surveillance
study [24]. In that study a total of 1936 and 1771 of
E.coli and Klebsiella pneumoniae were isolated in 2 year
period from 1st January 1998 to 31st December 1999.
Majority of these isolates were from urine specimens,
others were from pus, blood and other routine
specimens. Escherichia coli were 80%, 28%, 5%, 77%, 8%,
76%, 32% and 13% resistant to ampicillin, amoxicillin/
clavulanic acid, ceftazidime, tetracycline, gentamicin, co-
trimoxazole, nitrofurantoin and quinolones while the
rates of resistance to similar antibiotics for Klebsiella
pneumoniae were 85%, 32%, 6%,66%, 14%, 69%, 53% and
6% respectively.Extended –spectrum beta-lactamase (ESBL) producing
Escherichia coli and Klebsiella pneumoniae
Data on ESBL producing E. coli and Klebsiella
pneumoniae are limited in all the countries under re-
view. Of 302 E. coli tested for ESBL production in these
countries 88/302 (29%) were found to be ESBL
producers while of 283 Klebsiella pneumoniae tested
116/282 (41%) were ESBL producers [3,19,27-30]. Differ-
ent ESBL alleles have been reported including CTX-M
-15 Escherichia coli ST 131 which has been reported
worldwide [28]. Other reported alleles include TEM-63,
SHV-2a and SHV-12 [29].
Table 3 Antimicrobial resistance rates of Escherichia coli and Klebsiella pneumoniae from the blood, Mozambique and
Tanzania (ref: [22-26])
Antibiotic Resistance rate in different studies % Escherichia coli (range) Mean resistance n/N* (%)
Ampicillin 84, 96 , 85, 100, 96 (84–100) 227/240 (95)
Augmentin 40, 25, 69, 86 (25–86) 47/86 (55)
Tetracycline 55, 59 (55–59) 28/49(57)
Gentamicin 13, 29, 46, 68, 28 (13–68) 87/234 (37)
Co-trimoxazole 72, 87, 54, 77, 90 (54–90) 173/227 (76)
Ciprofloxacin 40, 8, 8, 4 (4–40) 13/86 (15)
Ceftriaxone 12, 54, 50 (12–54) 23/59(38)
Ceftazidime 0.0, 12, 50, 50 (0–50) 24/86 (28)
Meropenem 0.0, 0.0, 4 (0–4) 1/59 (2)
Resistance rate in different studies % Klebsiella pneumoniae (range)
Ampicillin 91, 100, 100, 100, 100 (91–100) 202/206 (98)
Augmentin 32, 47, 38, 84 (32–84) 97/194 ( 50)
Tetracycline 67, 62 (62–67) 91/141(65)
Gentamicin 40, 47, 47, 67, 18 (18–67) 91/206 (44)
Co-trimoxazole 63, 63, 94, 79, 70 (64–94) 151/206 (74)
Ciprofloxacin 0.00, 0.00, 0.00, 8 (0–8) 4/194 (2)
Ceftriaxone 50 25/50 (50)
Ceftazidime 6, 21, 15, 49 (6–49) 42/184 (22)
Meropenem 0.00, 0.00, 2 (0–2) 1/160 (1)
N*=Total number of isolates tested.
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There is increase trend of Salmonella spp causing blood
stream infection in developing countries especially
among HIV/AIDS patients. In these countries most of
Salmonella spp from the blood were found to be resist-
ant to ampicillin, co-trimoxazole and chloramphenicol
(Table 4) while being sensitive to ciprofloxacin
[26,31-37]. An increased resistance trend of Salmonella
spp to ciprofloxacin in DRC from 0.0% in 2009 to 15.4%
in 2012 was noted [32,33].Salmonella spp, Shigella spp, Vibrio cholera,
Campylobacter spp and diarrheagenic E.coli; and their
susceptibility patterns
Diarrheal diseases account for approximately 25% of all
deaths in <5 year-old children in developing countries
[38,39] and common pathogens (Campylobacter spp, Sal-
monella spp, Shigella spp and Diarrheagenic E. coli) causing
diarrhea in human have been found in animals. Except for
erythromycin resistance rates to ampicillin, co-trimoxazole,
chloramphenicol and tetracycline are higher among
Shigella spp than Salmonella spp in these countries
(Table 5) [40-45]. Shigella spp have been found to be com-
mon in DRC and it was noted that more than 50% of Shi-
gella spp from that country were multi-drug resistant
strains. This is a 4-fold increase compared to a study whichwas done in 1964 which demonstrated resistance to two
antibiotics to be 10% [42,45].
Five studies [46-50] reported on Vibrio cholera with four
of them reporting on the susceptibility pattern of Vibrio
cholera among isolates obtained during outbreaks [47-50].
In Zambia [47],Vibrio cholera 01 strains isolated from first
two outbreaks (1990–1991), showed a low level resistance
(2-3%) to tetracycline. The use of tetracycline caused the re-
sistance to increase to 95% in the subsequent outbreaks in
1992. Similar observations were reported in Tanzania [48],
whereby it was noted that there was an increase in resist-
ance patterns against V. cholera between outbreaks oc-
curred in 1997 and later outbreaks in1999 (Figure 1). In
Mozambique; of 175 rectal swabs or stool samples from pa-
tients with diarrhea, 58 strains of V. cholerae 01 were
isolated between January 7 and March 8, 2004. The anti-
microbial susceptibility of 15 isolates showed that all strains
were sensitive to tetracycline, ampicillin, furazolidine,
erythromycin and ciprofloxacin but resistant to co-
trimoxazole [49].
Five studies [51-55] investigated the presence di-
arrheagenic E. coli strains in these countries with 3 of stud-
ies [51,52,54] describing susceptibility pattern to various
antibiotics. The mean resistance rates of diarrheagenic E. coli
isolated in these countries for ciprofloxacin, nitrofurantoin,
co-trimoxazole, chloramphenicol, tetracycline, erythromycin
and ampicillin are seen in Table 5.
Table 4 Antimicrobial resistance rates of Salmonella spp from the blood, Zambia, DRC, Mozambique and Tanzania
ref: [26,32,33,37]
Antibiotic Resistance rates in different studies % (range) Mean resistance n/N* (%)
Ampicillin 100, 65, 74, 69 (65–100) 477/620(77)
Co-trimoxazole 100, 58, 66, 38 (38–100) 404/620 (65)
Chloramphenicol 100, 40, 55, 85 (40–100) 434/620 (70)
Gentamicin 16, 23 (16–23) 78/400(20)
Ciprofloxacin 0, 8, 15 (0–15) 32/225 (14)
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diarrhea in children but only four short-term studies
could be found on the subject from Tanzania and
Mozambique [44,56-58]. The prevalence of campylobac-
ter infection in human in Tanzania was found to range
from 2.6% to 9.3% [56-58]. All these human studies from
Tanzania did not test for the susceptibility pattern of the
isolates. The other study [59] in the same area investi-
gated the presence of Campylobacter spp in domestic
ducks; found that 80% of ducks had thermophilic cam-
pylobacter infection. Of 50 isolates tested for susceptibil-
ity pattern 48%, 74% and 82% were resistant to
cefuroxime, tetracycline and amoxycillin respectively
while 35% of the isolates were resistant to erythromycin.
The resistance rates to norfloxacin and ciprofloxacin
were 10% and 16% respectively (Table 6). InTable 5 Antimicrobial resistance rates of Salmonella spp, Shig
DRC, Mozambique and Tanzania
Antibiotic Resistance rate in different studies % Salmo
Ampicillin 25
Co-trimoxazole 78, 18 (18–78)
Chloramphenicol 15
Tetracycline 94, 15 (15–94)
Cefotaxime 14
Erythromycin 86
Resistance rate in different studies % Shigella s
Ampicillin 97, 56 (56–97)
Co-trimoxazole 97, 84 (84–97)
Chloramphenicol 94, 52 (52–94)
Tetracycline 98, 66 (66–98)
Erythromycin 19
Resistance rate in different studies % diarrheag
Ampicillin 72, 100 (72–100)
Co-trimoxazole 71, 60, 58 (58–71)
Chloramphenicol 45, 100 (45–100)




N*=Total number of isolates tested.Mozambique of 529 samples from children 9 (1.7%) had
campylobacter infection, all nine Campylobacter spp
strains isolated from children with diarrhea were suscep-
tible to erythromycin while 1 (11) was resistant to cipro-
floxacin [44].
Methicillin-resistant Staphylococcus aureus (MRSA) and
Health care-associated infections (HCAIs)
The WHO estimates that health care-associated infec-
tions (HCAIs) in developing countries are found in
15.5% of admissions, which is 3 times higher than the
rate in developed countries [60,61]. One form of infec-
tion, the surgical site infection, is particularly common
in developing countries due to the economic constraints
of hospitals and lack of hygiene, infection prevention
strategies and staff [29,62-66]. Staphylococcus aureus hasella spp and diarrheagenic E. coli from the stool, Zambia,
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Figure 1 Pattern of resistance of Vibrio cholerae isolates from Tanzania to tetracycline (TET), erythromycin (E), nalidixic acid (NA) and
chloramphenicol/co-trimoxazole in 1997 and 1999.
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in these countries with 13% of the bacteria exhibiting
MRSA phenotype (Table 7). Interestingly, the prevalence
of MRSA in Tanzania has been increasing, at the
Muhimbili National Hospital, the prevalence was 0.4% in
1999 [66], 2% in 2004 [24], and 23.3% in 2010 [25]. At
the Bugando Medical Center (BMC), the prevalence of
MRSA was 16.3% [67] in 2009 and 18.8% in 2011 [61].
Nine studies [26,62,63,67-72] reported the resistance
patterns of Staphylococcus aureus with only two studies
providing molecular insights of MRSA. The meanTable 6 Antimicrobial resistance rates of Escherichia coli from
Tanzania and Zambia (ref: [51,59,74,77])
Antibiotic Resistance rate in different studies: Es
Ampicillin 80, 90, 88 (80–90)
Augmentin 82, 74, 83 (74–83)
Gentamicin 63, 67 (63–67)
Co-trimoxazole 36, 71, 91 (36–91)
Tetracycline 4, 96 (4–96)
Resistance rates Campylobacter jejuni % (r
Amoxicillin 82
Tetracycline 74, 22 (22–74)
Erythromycin 35, 0.0 (0–35)
Cefuroxime 48
Norfloxacin 10
Ciprofloxacin 16, 11 (11–16)
N*=Total number of isolates tested.resistance rates ranges from 5% to 88% to various antibi-
otics as seen in Table 7. Regarding spa types, sixteen dif-
ferent spa types (t012, t021, t122, t186, t279, t701, t1855,
t1877, t224, t084, t304, t934, t1247, t2864, t7722 and
t7723) were observed in one study in Zambia [69], while
in Tanzania; the new MRSA clone ST1797/t7231 has
been isolated thus emphasizing the diversity of MRSA
clones in Africa [72]. In Mozambique; of 24 MRSA iso-
lates 6(25%), 3(12.5%) and 1(4.2%) were also resistant to
tetracycline, erythromycin and co-trimoxazole and only
1 strain was resistant to all antibiotics tested [26].animals and Campylobacter spp in Mozambique,













Table 7 Antimicrobial resistance rates of Staphylococcus aureus, Zambia, DRC, Mozambique and Tanzania
(ref: [26,62,68-72])
Antibiotic Resistance rate in different studies % (range) Mean resistance n/N* (%)
Penicillin 90, 90, 85 (85–90) 291/329 (88)
Erythromycin 35, 5, 7 (5–35) 51/327 (16)
Clindamycin 22 10/46 (22)
Co-trimoxazole 31, 73 (31–73) 145/278 (52)
Chloramphenicol 37, 7 (7–37) 63/287 (22)
Gentamicin 5 9/182 (5)
Tetracycline 48, 28 (28–48) 56/147 (38)
MRSA 31, 16, 2, 27, 2, 8 (2–31) 317/2472 (13)
N*=Total number of isolates tested.
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Eight reviewed studies [51,59,73-78] investigated the
magnitude of bacterial diseases in animals with only 4
studies [51,59,77,78] reporting resistance profile to vari-
ous antibiotics. As for Escherichia coli from human;
Escherichia coli from animals exhibited high resistance
rates ranging from 50% for tetracycline to 86% for ampi-
cillin (Table 7). Salmonella enteritidis was found to con-
taminate 3.8% and 4.7% of eggs and chicken carcasses
respectively. All Salmonella enteritidis isolates were
found to be sensitive to gentamicin, ampicillin, tetracyc-
line, co-trimoxazole, amoxicillin, furazolidine and
chloramphenicol.
Discussion
In the developing countries under review, there are limited
data from large surveillance studies on antimicrobial resist-
ance. In addition few short clinical studies document the
susceptibility pattern of common pathogens from human
and animals. This may partly be due to the lack of micro-
biological facilities in many health facilities in developing
countries [79]. Our findings emphasize the need for coordi-
nated efforts to improve the diagnosis of infectious diseases
in developing countries coupled with surveillance of anti-
microbial resistance in these countries. Together with the
increased effort by WHO to control malaria transmission,
other potential causes of fever should be taken into consid-
eration; and appropriate antibiotic treatment will reduce
morbidity and mortality resulting from other causes of
fever.
Despite few studies blood stream and urinary tract infec-
tions have been found to be common in these countries as
demonstrated in this review and it should be noted that the
endemicity of HIV has changed their epidemiology in Af-
rica. Apart from Salmonella spp; multi-drug Escherichia
coli and Klebsiella pneumoniae were found to be common
causes of blood stream infections and UTI. Increased trend
of these isolates to become resistant to ampicillin, gentami-
cin and third generations’ cephalosporins was noted; this
could be due to overuse of these drugs in the communityand hospitals, in all countries reviewed no clear antibiotic
policy was found.
ESBL has been found to be a threat, especially as a cause
of nosocomial infections. Prevalence as high as 50% have
been observed among Klebsiella pneumoniae from inpa-
tients in these countries. The occurrence of the Escherichia
coli clone ST 131 in Tanzania confirms that resistant clones
can spread from one part of the world to another [28]. Low
mean resistance rates to meropenem were observed in
these countries; this could be explained by the fact that this
drug is expensive and not available in the market. There is
an urgent need of antibiotic policy in these countries be-
cause in countries where carbapenems have been misused,
such as India or Pakistan, outbreaks of carbapenems resist-
ant Escherichia coli and Klebsiella pneumoniae have been
experienced [11]. Recently, the emergence of NDM-1 plas-
mid mediated carbapenems resistance has been noted,
spreading from India to Europe, USA and Africa. Joint ef-
forts are needed to control the spread of NDM-1.
In this review few studies were found to address en-
teric pathogens, it was noted that Shigella spp were
more resistance than Salmonella spp; an increase trend
of multi--drug resistant Shigella spp in DRC was noted.
Similarly most of diarrheagenic Escherichia coli were re-
sistant to commonly used antibiotics (ampicillin, co-
trimoxazole, tetracycline and erythromycin). This could
be due to self prescription of these antibiotics for the
treatment of diarrhea episodes as evidenced by increased
resistance of Vibrio cholerae strains between outbreaks
in Zambia and Tanzania. In all countries under review,
many patients buy antibiotics from private pharmacies
and drug shops for self-medication before seeking med-
ical professional care [80-82]. In addition Campylobacter
spp were found to be resistant to ciprofloxacin,
cefuroxime and erythromycin. This situation needs to be
further investigated with standardize microbiological
method so that the real magnitude can be established or
confirmed.
In addition, MRSA appears to be an emerging prob-
lem; the problem might be underestimated because not
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identification. However Staphylococcus aureus has been
the major cause of SSI, as documented in few studies
from these countries. The increase trend of MRSA as
noted in Tanzania; necessitate the coordinated surveil-
lance to determine the evolution of these strains in
Africa. MRSA isolates have been isolated from animals
and we need, therefore, to compare the genotypes be-
tween animals and humans, as evidenced by the diversity
of MRSA genotypes in Tanzania and Zambia [68-70].
Few laboratories are routinely conducting testing for
ESBL and MRSA detection. This observation stresses
the need for governmental and non- governmental orga-
nizations to provide sustainable support to improve la-
boratory capacity in developing countries. This should
go hand in hand with the establishment of a quality as-
surance system to ensure quality microbiological results
from all laboratories. As noted in Tanzania, there is an
increased resistance trend to ceftriaxone and ceftazidime
among isolates causing nosocomial infections. Improving
diagnostic facilities and research capacity to determine
the evolution of ESBL and MRSA clones in Africa is no
longer an option but is mandatory, especially when the
treatment of ESBL producing isolates and MRSA
becomes too expensive for countries like DRC,
Mozambique, Tanzania and Zambia.
Unauthorized use of antibiotics seems to be common,
both in medical and veterinary settings. While we have
found no evidence linking antimicrobial resistance in
human cases with the use of similar antibiotics in ani-
mals, there is a need for a coordinated one health based
surveillance of the antimicrobial resistance in humans
and animals. It appears also relevant to follow the rec-
ommendations of the Joint FAO-OIE-WHO on non-
human antimicrobial usage.
Conclusions
Relevant information on bacterial diseases is limited in
DRC, Mozambique, Tanzania and Zambia. Moreover,
there are no national policies guiding surveillance. Lack
of detailed microbiological method was noted in various
studies with no detailed information regarding quality
assurance; but despite this limitation an increased trend
of resistance to commonly used antibiotics such as
ampicillin, co-trimoxazole, gentamicin, erythromycin,
tetracycline and third generation cephalosporins was
noted. This might be exacerbated by behavioral factors,
incentive motivate prescribing, and the dispensing and
purchasing of antibiotics when they are inappropriate
for treating a specific condition. Other contributing fac-
tors include the drugs’ quality or the use of partial doses,
and patients’ demand for symptomatic eradications. A
systematic national surveillance system is urgently
needed to provide data on the levels of bacterial diseasesand drug resistance in common pathogens from hospi-
tals and communities. In addition, a comparative mo-
lecular epidemiology study to compare human and
animals isolates is urgently needed to shade a light of
the transmission of bacterial pathogens, especially at the
community level. The rising incidence of MRSA and
ESBL infections points to the need to include the height-
ened the regimes for hospital facility cleanliness as part
of the policy for the use of antibiotics and antibiotic
stewardship in order to minimize the risk of hospital-
acquired infections with MRSA and ESBL producing
isolates.
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